These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 16636678

  • 1. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
    Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C.
    Oncogene; 2006 Aug 24; 25(37):5145-54. PubMed ID: 16636678
    [Abstract] [Full Text] [Related]

  • 2. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A.
    Br J Haematol; 2005 Aug 24; 130(4):501-10. PubMed ID: 16098063
    [Abstract] [Full Text] [Related]

  • 3. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis.
    Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C.
    BMC Cancer; 2005 Jan 14; 5():5. PubMed ID: 15651986
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
    Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y.
    J Urol; 2007 May 14; 177(5):1894-9. PubMed ID: 17437844
    [Abstract] [Full Text] [Related]

  • 5. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions.
    Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):198-202. PubMed ID: 19695436
    [Abstract] [Full Text] [Related]

  • 6. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O, Wu X, Jin X, Nouh MA, Fiscella M, Albert V, Matsuda T, Kakehi Y.
    Urology; 2007 Feb 01; 69(2):395-401. PubMed ID: 17320696
    [Abstract] [Full Text] [Related]

  • 7. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA.
    Cancer Res; 2007 Jul 15; 67(14):6987-94. PubMed ID: 17638911
    [Abstract] [Full Text] [Related]

  • 8. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
    Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, Wang Y, Qian Q, Qian C, Wu J, Liu XY.
    Cancer Res; 2006 Apr 15; 66(8):4291-8. PubMed ID: 16618754
    [Abstract] [Full Text] [Related]

  • 9. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, Albert V, Muto M, Yoshida H, Aoki M, Tamada T, Kuroki R, Yoshida H, Ishida I, Ware CF, Kataoka S.
    Clin Cancer Res; 2005 Apr 15; 11(8):3126-35. PubMed ID: 15837769
    [Abstract] [Full Text] [Related]

  • 10. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.
    Gene Ther; 2006 Feb 15; 13(4):330-8. PubMed ID: 16195699
    [Abstract] [Full Text] [Related]

  • 11. Targeting death-receptors in radiation therapy.
    Niemöller O, Belka C.
    Results Probl Cell Differ; 2009 Feb 15; 49():219-39. PubMed ID: 19582410
    [Abstract] [Full Text] [Related]

  • 12. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, Tong Y, Liang M, Hu F, Chen HZ.
    Int J Mol Med; 2005 Dec 15; 16(6):1179-84. PubMed ID: 16273304
    [Abstract] [Full Text] [Related]

  • 13. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
    MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM.
    Cancer Res; 2005 Dec 15; 65(24):11265-70. PubMed ID: 16357130
    [Abstract] [Full Text] [Related]

  • 14. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
    Younes M, Georgakis GV, Rahmani M, Beer D, Younes A.
    Eur J Cancer; 2006 Mar 15; 42(4):542-7. PubMed ID: 16426839
    [Abstract] [Full Text] [Related]

  • 15. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL, Zou WY, Song LH, Wei W.
    Cancer Chemother Pharmacol; 2005 Feb 15; 55(2):189-96. PubMed ID: 15290100
    [Abstract] [Full Text] [Related]

  • 16. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge].
    Belka C, Betsch A, Marini P, Jendrossek V, Bamberg M, Budach W.
    Strahlenther Onkol; 2003 Mar 15; 179(3):141-51. PubMed ID: 12627256
    [Abstract] [Full Text] [Related]

  • 17. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK.
    J Clin Oncol; 2005 Dec 20; 23(36):9394-407. PubMed ID: 16361639
    [Abstract] [Full Text] [Related]

  • 18. The importance of abrogation of G2-phase arrest in combined effect of TRAIL and ionizing radiation.
    Rezácová M, Vávrová J, Vokurková D, Tichý A, Knízek J, Psutka J.
    Acta Biochim Pol; 2005 Dec 20; 52(4):889-95. PubMed ID: 16025160
    [Abstract] [Full Text] [Related]

  • 19. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
    Mikami T, Koyama T, Koyama T, Imakiire A, Yamamoto K, Furuhata M, Toyota H, Mizuguchi J.
    Anticancer Res; 2006 Dec 20; 26(2A):1153-60. PubMed ID: 16619517
    [Abstract] [Full Text] [Related]

  • 20. Characterization of monoclonal antibodies directed against trail or trail receptors.
    Vermot-Desroches C, Sergent E, Bonnin B, Wijdenes J.
    Cell Immunol; 2005 Dec 20; 236(1-2):86-91. PubMed ID: 16157319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.